All News

Despite the belantamab mafodotin regimen improving overall survival in patients with relapsed or refractory multiple myeloma, the trial is ongoing to confirm the presented results.

The vice president and chief pharmacy officer at City of Hope explains how she serves as a mentor for women within health care, the importance of networking, and staying educated.

These employees build operational workflows, predictive analytical tools, implement and refine clinical decision support technologies, increase efficiency, and more.

The pharmacy supply chain and reimbursement marketplace are broken, manufacturers are throwing up their hands and getting into the vertical integration scrum

Cardinal Health released its 2024 biosimilars report, including research and in-depth analyses on legislative development, payer landscapes, and new treatments in the pipeline.

The vice president and chief pharmacy officer of City of Hope discusses obstacles women face in health care and how diversity, equity, and inclusion can be promoted within the space.

Patients with urothelial carcinoma who were treated with the nivolumab-based regimen had better OS and PFS compared with those who received cisplatin with gemcitabine alone.

The application was previously granted fast track designation and orphan drug designation.

Individuals with persistent asthma and at least 1 complex comorbidity were more likely to use telemedicine, the results of the study showed.

Promising data have emerged suggesting a significant weight loss benefit for patients using GLP-1 agonists and GLP-1/GIP dual agonists.

The study is a companion study to the ROCKstar study, which investigated the drug in individuals with cGVHD who received 2 to 5 prior lines of therapy.

“I see clinical pharmacy specialists (CPS) to be more like the frontline folks that would pretty much work very closely with the providers,” according to a CPS at City of Hope.

The designation is for all patients with low-grade serous ovarian cancer, regardless of their KRAS status and after 1 or more prior lines of therapy.

Continuous glucose monitoring (CGM) is a valuable tool in managing diabetes, offering real-time data on glucose levels throughout the day.

Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous.

Diabetes is a known risk factor for cognitive decline and small vessel disease.

Vitamin D preserved insulin-producing cells and cell function, which can reduce complications in young patients.

They also compared the approach of the European Medicines Agency and the FDA in drug approvals.

The device conducts blood biomarker tests that accurately diagnose amyloid pathology and can assist in diagnosing Alzheimer disease in patients with cognitive impairment.

The at-home test offers the availability to assess for all viruses using one tool.

Findings emphasize the importance of further research on effective and safe alternative treatments for MDD in children and adolescents, specifically in patients who are refractory to nonpharmacologic treatment and/or standard of care antidepressants

Findings showed that pharmacists frequently communicated with patients to implement complex plans.

A phase 1 study previously demonstrated that MW032 and denosumab were bioequivalent in pharmacokinetics, pharmacodynamics, safety, and immunogenicity.

Artificial intelligence (AI) recommendations resulted in fewer recurrent strokes, heart attacks, or vascular death within 3 months of a previous ischemic stroke.

This episode highlights how celebrity endorsements and local influencers can be leveraged to address vaccine hesitancy by shaping attitudes, but also must account for factors like audience trust and the potential for both benefits and limitations.

The continuous glucose monitoring system will be available for purchase online and without a prescription starting in summer 2024.

The CORe initiative is aimed at promoting inclusivity, reducing startup time for clinical trials, and facilitating data sharing to address recruitment and retention challenges in cancer research at community oncology sites.